%0 Journal Article
%A Ugurel, Selma
%A Abu Rached, Nessr
%A Gambichler, Thilo
%A Mengoni, Miriam
%A Tüting, Thomas
%A Hassel, Jessica C
%A Reschke, Robin
%A Lodde, Georg C
%A Placke, Jan-Malte
%A Schadendorf, Dirk
%A Reinhardt, Lydia
%A Kreuter, Alexander
%A Gschnell, Martin
%A Utikal, Jochen
%A Erdmann, Michael
%A Dücker, Pia
%A Helbig, Doris
%A Franklin, Cindy
%A Gebhardt, Christoffer
%A Poch, Gabriela
%A Kähler, Katharina C
%A Weichenthal, Michael
%A Gutzmer, Ralf
%A Heinzerling, Lucie
%A Weishaupt, Carsten
%A Mohr, Peter
%A Thoms, Kai-Martin
%A Lang, Berenice
%A Schilling, Bastian
%A Haferkamp, Sebastian
%A Sachse, Michael
%A Welzel, Julia
%A Jochims, Franziska
%A Raap, Ulrike
%A Schley, Gaston
%A Terheyden, Patrick
%A Dippel, Edgar
%A Pöttgen, Christoph
%A Becker, Jürgen C
%A Tasdogan, Alpaslan
%A Amaral, Teresa
%A Nanz, Lena
%A Leiter, Ulrike
%T Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.
%J European journal of cancer
%V 228
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-01861
%P 115750
%D 2025
%X For rare skin cancers, few data exist on the outcome of systemic therapies, particularly immune checkpoint inhibition (ICI). The present study analysed the real-world use of different systemic therapies including ICI, and its outcome in patients with advanced rare skin cancers.This retrospective multicenter study included patients who received systemic therapy for advanced, non-resectable cutaneous angiosarcoma (AS), Kaposi sarcoma (KS), pleomorphic dermal sarcoma (PDS), or cutaneous adnexal carcinoma (CAC). Study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS).209 patients (77 AS; 81 KS; 14 PDS; and 37 CAC) from 30 centers were included. As first-line treatment AS and KS patients predominantly received chemotherapy (77.9 
%K Angiosarcoma (Other)
%K Chemotherapy (Other)
%K Cutaneous adnexal carcinoma (Other)
%K Immune checkpoint inhibition (Other)
%K Kaposi sarcoma (Other)
%K Pleomorphic dermal sarcoma (Other)
%K Targeted therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40912056
%R 10.1016/j.ejca.2025.115750
%U https://inrepo02.dkfz.de/record/304468